News
Feed
Events
Feed
News
+ Events
Feed

Relief Therapeutics Holding SA

  • ISIN CH0100191136
  • Country Switzerland

Latest News

17 March 2023

22:45 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

16 March 2023

07:00 Corporate

Relief Therapeutics Holding SA

Corporate

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

15 March 2023

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ 

28 February 2023

07:00 Corporate

Relief Therapeutics Holding SA

Corporate

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars

14 February 2023

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa

8 February 2023

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Provides an Update on its Financing Strategy

17 January 2023

06:56 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma

27 December 2022

07:15 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

20 December 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

14 December 2022

07:00 Corporate

Relief Therapeutics Holding SA

Corporate

Relief Therapeutics to Participate in January Investor Meetings

13 December 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

8 December 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces Executive Leadership Team Changes

21 November 2022

07:00 Corporate

Relief Therapeutics Holding SA

Corporate

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

16 November 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

14 November 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

8 November 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

7 November 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

26 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement

25 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

14 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

10 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Announces U.S. Launch of PKU GOLIKE

6 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

3 October 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

22 September 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children’s Hospital of Chicago

15 September 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Reports Half-Year 2022 Results and Provides Corporate Update

12 September 2022

07:05 Corporate

Relief Therapeutics Holding SA

Corporate

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

7 September 2022

07:00 Corporate

Relief Therapeutics Holding SA

Corporate

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

24 August 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission

22 August 2022

07:00 Ad-hoc

Relief Therapeutics Holding SA

Ad-hoc

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation

Upcoming Events

No Events found